Skip to main content
Clinical Trials/CTRI/2020/07/026759
CTRI/2020/07/026759
Completed
未知

Evaluation and Validation of the clinical performance of VITROS Anti SARS COV2 Total assay in the COVID-19 patient population and commercialization of the Assay on VITROS 3600

Ortho Clinical Diagnostics0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Ortho Clinical Diagnostics
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Ortho Clinical Diagnostics

Eligibility Criteria

Inclusion Criteria

  • Covid 19 RT PCR positive patients having typical symptoms for about a minimum of 8 days will be assayed using VITROS® CoV2T assay in VITROS® 3600 or 5600 systems.
  • Asymptomatic health care professionals, will be tested using VITROS® Anti SARS CoV2 Total assay on the VITROS® 3600 Immunodiagnostics or VITROS® 5600 Integrated System.
  • Samples from normal healthy adult asymptomatic individuals (collected before Nov., 2019\) will be tested using VITROS® Anti SARS CoV2 Total assay on the VITROS® 3600 Immunodiagnostics or VITROS® 5600 Integrated System.

Exclusion Criteria

  • Exclude samples from patients for whom the time between symptom onset and collection of samples cannot be determined.
  • Exclude grossly hemolyzed, icteric or turbid samples, or samples with visible particulates that are not getting removed even after centrifugation.

Outcomes

Primary Outcomes

Not specified

Similar Trials